Answers are grounded in this paper and cite their sources.
To assess the efficacy and safety of risdiplam (EVRYSDI®) in infants with presymptomatic spinal muscular atrophy (SMA).
No takes yet. Share an insight, caveat, or question.
Servais et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: